Travere’s Filspari overcomes Phase 3 fail to become first drug for rare kidney disease
The FDA has given the go-ahead to Travere Therapeutics’ endothelin blocker Filspari for the treatment of focal segmental glomerulosclerosis, a rare and potentially fatal kidney disease that analysts expect could open a market opportunity over $2 billion. “ …